--- title: "08:10 ETEMBC Alert: Hagens Berman Investigates Alleged Securities Law Violations at Embecta Corp. (NASDAQ: EMBC) Following Pending Class Action Litigation" type: "News" locale: "en" url: "https://longbridge.com/en/news/294063707.md" description: "Hagens Berman is investigating Embecta Corp. (NASDAQ: EMBC) for alleged securities law violations following a class action lawsuit. The suit claims Embecta misled investors about the stability of its insulin pen needle business while suffering significant share losses. On May 5, 2026, Embecta revealed massive revenue declines, slashed EPS guidance by 43%, and cut dividends by 93%, causing its stock to plummet 57.8%. Investors who suffered losses during the class period are encouraged to contact the firm." datetime: "2026-07-28T12:11:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294063707.md) - [en](https://longbridge.com/en/news/294063707.md) - [zh-HK](https://longbridge.com/zh-HK/news/294063707.md) --- # 08:10 ETEMBC Alert: Hagens Berman Investigates Alleged Securities Law Violations at Embecta Corp. (NASDAQ: EMBC) Following Pending Class Action Litigation , /PRNewswire/ -- Hagens Berman, a leading national shareholder rights law firm, is conducting an investigation into Embecta Corp. (NASDAQ: EMBC) regarding alleged violations of federal securities laws. This investigation follows the recent filing of a class action lawsuit in the U.S. District Court for the District of New Jersey, which alleges that Embecta misrepresented the commercial stability of its insulin pen needle business. The firm encourages Embecta investors who suffered substantial losses to submit your losses now. **Class Period:** Nov. 25, 2025 – May 4, 2026 **Lead Plaintiff Deadline:** Aug. 17, 2026 **Visit:** www.hbsslaw.com/investor-fraud/embc **Contact the Firm Now:** \[email protected\] 844-916-0895 **Focus of Embecta (EMBC) Securities Class Action:** The pending securities class action alleges that Embecta and its management misled investors regarding the stability and commercial strength of its core insulin pen needle business. The complaint contends that throughout the class period, Embecta repeatedly assured investors that its pen needle portfolio was "stable," "resilient," and "incredibly resolute." Plaintiffs allege these statements were materially false and misleading because, in reality, the company was experiencing significant competitive share loss—particularly at a major customer—and broader market volume softness in the retail channel, all of which management allegedly knew or recklessly disregarded while reaffirming its positive financial guidance. The truth behind these alleged misrepresentations was revealed on May 5, 2026, when in delivering its second-quarter fiscal 2026 financial results Embecta admitted to a massive revenue decline, citing specific headwinds in the U.S. pen needle market that contradicted its prior assurances. The company slashed its full-year 2026 adjusted EPS guidance by approximately 43% at the midpoint and announced a drastic 93% reduction in its quarterly dividend, dropping it from $0.15 to $0.01 per share. The market response to this news was immediate and severe, causing Embecta's stock price to plummet 57.8% over a single trading day. "We are investigating whether Embecta's assurances were misleading, given that the company later reported a significant revenue decline and cited market volume softness," said **Reed Kathrein**, the Hagens Berman partner leading the firm's investigation of the pending claims. **Investor Rights** Investors who purchased or acquired Embecta common stock during the Class Period are encouraged to contact our legal team. - Report your losses to HBSS - **Email**: \[email protected\] - **Phone**: 844-916-0895 If you'd like more information and answers to other frequently asked questions about the Embecta case and the firm's investigation, read more » **Whistleblowers:** Persons with non-public information regarding Embecta should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at **844-916-0895** or email \[email protected\]. About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. Attorney Advertising. Prior results do not guarantee a similar outcome in any future case. Contact: Reed Kathrein, 844-916-0895 SOURCE Hagens Berman Sobol Shapiro LLP ### Related Stocks - [EMBC.US](https://longbridge.com/en/quote/EMBC.US.md) ## Related News & Research - [10:09 ETLost Money on Embecta Corp. (EMBC)? Join Class Action Suit Seeking Recovery - Contact SueWallSt](https://longbridge.com/en/news/294380044.md) - [04:40 ETEmbecta Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - EMBC](https://longbridge.com/en/news/293902730.md) - [EMBC DEADLINE: SueWallSt Reminds Embecta Corp. Investors of Upcoming Securities Class Action Deadline](https://longbridge.com/en/news/293631844.md) - [Lawsuit Notice: $EMBC Legal News: Embecta Insulin Pen Issues and 57% Stock Drop Trigger Securities Fraud Class Action](https://longbridge.com/en/news/293324860.md) - [04:03 ETEmbecta Corp. Investor Alert: Contact SBS by August 17, 2026 for Opportunity to Lead Securities Fraud Lawsuit](https://longbridge.com/en/news/294030575.md)